A Study Of Cannabis Withdrawal In Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) Or Chimeric Antigen Receptor T-cell (CAR-T) Therapy

Overview

About this study

The purpose of this study is to assess the prevalence of cannabis withdrawal and to characterize the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All adult patients admitted for BMT or CAR-T therapy will be recruited to participate in the study. At Mayo Clinic Arizona, the number of inpatient admissions for BMT was 221 over the last 12 months and CAR-T was 95 over the last 12 months.

Exclusion Criteria:

Individuals unable to provide informed consent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/02/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Osama Abulseoud, M.D.	Open for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Osama Abulseoud, M.D.

Open for enrollment

More information

Publications

Publications are currently not available

Clinical Trials